Navigation Links
Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
Date:8/21/2012

SAN DIEGO, Aug. 21, 2012 /PRNewswire/ -- Millennium Laboratories, the leading research-based clinical diagnostic company dedicated to improving the lives of people suffering from pain, announced today that it has initiated a first-of-its-kind, large-scale prospective clinical outcomes study of its pharmacogenetic test. The study, which will encompass more than 30 practice sites nationally, is designed to evaluate the relationship between CYP genotype, as determined by Millennium Pharmacogenetic Testing (PGT), and clinical outcomes including level of analgesia, functional status, and clinically significant opioid-related adverse events. The study will also seek to assess the benefit to prescribers of pharmacogenetic information arising from Millennium PGT, and characterize any corresponding changes in prescribing patterns.

(Logo:  http://photos.prnewswire.com/prnh/20120516/LA07836LOGO)

"Our company's commitment to furthering the science and field of pain management includes providing research that supports best practices," said Howard Appel, President of Millennium Laboratories. "To that end, this study will seek to expand and improve an understanding of how genetic variability affects response to prescribed medications to help improve medication choices and efficacy, and minimize side effects – potentially resulting in improved patient care."  

"Pharmacogenetic testing can provide valuable information through the detection of genetic variations in enzymes associated with the metabolism of medications commonly prescribed to patients suffering from debilitating chronic pain and pain-related effects. Utilized in combination with urine drug testing, it offers significant potential to improve the safety and efficacy of drug treatment and reduce adverse effects among certain patients," said Michael Brennan, M.D., a nationally recognized pain specialist practicing in Fairfield, Connecticut. "Ongoing research such as the major study announced today by Millennium will be critical in helping to facilitate a better understanding of the important role this new tool can play in pain management."

The largest study of its kind, up to 1,250 subjects meeting the study entry criteria will be enrolled into the initial, cross-sectional phase. Subjects categorized by the test as poor or ultra-rapid metabolizers will continue into the longitudinal phase of the study.

About Millennium Pharmacogenetic Testing

Millennium PGT saliva-based testing detects genetic variations in enzymes associated with the metabolism of medications commonly prescribed to patients suffering from debilitating chronic pain and related symptoms. Designed to serve as an objective tool to support individualized therapy, the test will help clinicians identify patients who may benefit from modifying the drug selection or dosing of certain prescribed opioids including methadone, benzodiazepines, tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs).

About Millennium Laboratories

Millennium Laboratories (http://millenniumlabs.com/) is the leading research-based, clinical diagnostic company dedicated to improving the lives of people with chronic pain. The company provides healthcare professionals with medication monitoring, drug detection and pharmacogenetic testing services to personalize treatment plans to improve clinical outcomes and patient safety.

Millennium's commitment to advancing the science of pain management includes a strong focus on industry research, education and advocacy. Through its association with the Millennium Research Institute, a nonprofit national research center, it has gained respect as a leader in providing healthcare professionals with education and research to advance the assessment and management of chronic pain.


'/>"/>
SOURCE Millennium Laboratories
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
2. Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences
3. Millennium Surgical Corp. Announces Sales Figures, Growth
4. Millennium Surgical Corp. Develops Online Sterilization Resource Center
5. Court Preliminarily Deems Millennium Laboratories Press Release Misleading
6. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
7. SpineMark Corporation Partners with PhDx and Millennium Environmental to Create an ISO type Spine Protocol Management System
8. Pharmacy Industry Veteran Joins Millennium Pharmacy Systems as SVP Operations
9. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
10. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
11. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... Global Health Intelligence (GHI), the leading healthcare data analytics ... 2017 ranking of the Best-Equipped Hospitals in Latin America ... GHI,s hospitals database for Latin America , which is ... database covers 86% of the hospitals in Latin ... each institution in key areas such as beds, medical specialties, ...
(Date:5/10/2017)... , May 10, 2017 CSSi, the ... for the clinical research industry, is proud to announce ... . The new website features both enriched content and ... experience and enhances the company,s already well-established position as ... "After many months of hard work, ...
(Date:5/9/2017)... May 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of ... Canadian Intellectual Property Office has granted Oramed a ... of Exenatide". The patent covers Oramed,s invention of ... GLP-1 is an incretin hormone that stimulates the ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... , ... In any business, follow up is critical to success. It is ... presenting treatment, there will always be some patients who can’t or won’t make a ... practices when it comes to presenting treatment. After the patient leaves, most practices ...
(Date:5/26/2017)... YORK, NY (PRWEB) , ... May 26, 2017 ... ... Board (SAB) met this week to review more than eighty-nine grant submissions ... experienced and emerging young scientists in the Parkinson’s field.     , The American Parkinson ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... CareFusion NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware ... for diagnostic device operations. With this platform, initializing devices and importing studies are ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the Congressional Budget Office (CBO) ... House on May 4, would result in 23 million Americans losing their health insurance ... 2010 Patient Protection and Affordable Care Act (ACA). , “It is clear from ...
(Date:5/26/2017)... ... ... Rob Lowe acts as host and helps educate and inform the public using ... Viewers can reconnect with America as it explores some of the best places to ... for an inventive new place for a family vacation, and have discovered hiking. Many ...
Breaking Medicine News(10 mins):